Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2009

View Archived Issues

Recent Georgia Tech patent describes novel HDAC inhibitors

New MAPKAP-K2 (MK2) inhibitors reported in recent Novartis patent

Combination of YM-155, docetaxel and prednisone used in prostate cancer therapy

BIBF-1120 and BIBW-2992 may be used in combination in prostate cancer treatment

Bayer discloses prodrugs of apixaban for thromboembolic disorders

Merck & Co. discloses novel orexin receptor antagonists for insomnia

New HCV NS3/NS4 protease inhibitors reported in recent Gilead patent

PharmaMar licenses kahalalide F analogues to Marinomed

Catalyst halts enrollment into phase II trial of CPP-109 for methamphetamine addiction

MMI presents update on clinical development of GVX-3322 and ONCO-4417

2008 highlights at Elan

Anacor reports encouraging results from phase I AN-2718 trial

Pharmexa and Affitech enter into conditional merger agreement

MDV-3100 displays safety and antitumor activity in phase I/II trial for prostate cancer

Vertex to acquire ViroChem and its preclinical-stage polymerase inhibitors

FDA gives positive review of InNexus' IND plans for DXL-625 in NHL and CLL

Dronedarone reduces risk of hospitalization from cardiovascular events in atrial fibrillation

Meropenem/clavulanate combination inhibits extensively drug-resistant tuberculosis

Ferring launches degarelix for advanced prostate cancer

Quest presents positive results for its photosensitizer SL-052

4SC initiates phase IIa trial for 4SC-101 in Crohn's disease

Access announces results from a phase II ovarian cancer trial of ProLindac

CV Therapeutics reports phase I proof-of-concept data for CVT-3619

GlaxoSmithKline submits MAA for pazopanib in advanced kidney cancer

NICE refuses funding for advanced breast cancer treatment, Tyverb

Proteon initiates phase I/II PRT-201 study in hemodialysis patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...